 Truncated FGFR2 is a clinically actionable oncogene in multiple cancersDaniel Zingg,
Jinhyuk Bhin,
Julia Yemelyanenko,
Sjors M. Kas,
Frank Rolfs,
Catrin Lutz,
Jessica K. Lee,
Sjoerd Klarenbeek,
Ian M. Silverman,
Stefano Annunziato,
Chang S. Chan,
Sander R. Piersma,
Timo Eijkman,
Madelon Badoux,
Ewa Gogola,
Bjørn Siteur,
Justin Sprengers,
Bim Klein,
Richard R. Goeij- de Haas,
Gregory M. Riedlinger,
Hua Ke,
Russell Madison,
Anne Paulien Drenth,
Eline Burg,
Eva Schut,
Linda Henneman,
Martine H. Miltenburg,
Natalie Proost,
Huiling Zhen,
Ellen Wientjens,
Roebi Bruijn,
Julian R. Ruiter,
Ute Boon,
Renske Korte-Grimmerink,
Bastiaan Gerwen,
Luis Féliz,
Ghassan K. Abou-Alfa,
Jeffrey S. Ross,
Marieke Ven,
Sven Rottenberg,
Edwin Cuppen,
Anne Vaslin Chessex,
Siraj M. Ali,
Timothy C. Burn,
Connie R. Jimenez,
Shridar Ganesan (),
Lodewyk F. A. Wessels () and
Jos Jonkers ()
Nature, 2022, vol. 608, issue 7923, 609-617 Abstract: Abstract Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer1. However, clinical responses to FGFR inhibitors have remained variable1–9, emphasizing the need to better understand which FGFR2 alterations are oncogenic and therapeutically targetable. Here we apply transposon-based screening10,11 and tumour modelling in mice12,13, and find that the truncation of exon 18 (E18) of Fgfr2 is a potent driver mutation. Human oncogenomic datasets revealed a diverse set of FGFR2 alterations, including rearrangements, E1–E17 partial amplifications, and E18 nonsense and frameshift mutations, each causing the transcription of E18-truncated FGFR2 (FGFR2ΔE18). Functional in vitro and in vivo examination of a compendium of FGFR2ΔE18 and full-length variants pinpointed FGFR2-E18 truncation as single-driver alteration in cancer. By contrast, the oncogenic competence of FGFR2 full-length amplifications depended on a distinct landscape of cooperating driver genes. This suggests that genomic alterations that generate stable FGFR2ΔE18 variants are actionable therapeutic targets, which we confirmed in preclinical mouse and human tumour models, and in a clinical trial. We propose that cancers containing any FGFR2 variant with a truncated E18 should be considered for FGFR-targeted therapies. Date: 2022 Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:608:y:2022:i:7923:d:10.1038_s41586-022-05066-5 Ordering information: This journal article can be ordered from DOI: 10.1038/s41586-022-05066-5 Access Statistics for this article Nature is currently edited by Magdalena Skipper More articles in Nature from Nature |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.